NEW YORK (GenomeWeb News) - Medvet Science will distribute Agendia’s MammaPrint breast cancer prognosis test to hospitals in Australia, Agendia said today.
The Dutch company said its microarray-based test was developed from a 70-gene tumor expression profile that predicts disease outcome, and will be used by physicians to help plan follow-up therapy.
Agendia CEO Bernhard Sixt said the Australia agreement is part of the company’s planned global expansion for the test. Medvet also has agreements in place with companies to market the test in South America, the UK, and South Africa.
The test may “reduce consequences and associated costs of post-operative treatment,” said Greg Johansen, general manager of Adelaide-based Medvet.